This trial is testing if a drug can improve learning, problem solving, and memory in people with dementia with Lewy Bodies.
- Dementia with Lewy Bodies (DLB)
1 Primary · 3 Secondary · Reporting Duration: 16 weeks
2 Treatment Groups
1 of 2
1 of 2
160 Total Participants · 2 Treatment Groups
Primary Treatment: Neflamapimod · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is it possible to enroll in this scientific investigation at present?
"That is correct. According to clinicaltrials.gov, this medical trial was originally posted on May 1st 2023 and remains open for recruitment as of the 17th of May in the same year. Presently, 160 patients need to be recruited from only a single site." - Anonymous Online Contributor
How many individuals are currently enrolled in the trial?
"Affirmative. Clinicaltrials.gov affirms that this clinical trial is still seeking participants; the study was first posted on May 1st 2023 and subsequently edited on the 17th of the same month. The goal is to recruit 160 individuals from a single medical site." - Anonymous Online Contributor
Has Neflamapimod been sanctioned for medical use by the FDA?
"Our team has given Neflamapimod a score of 2 as the Phase 2 trial provides some proof that it is safe but does not provide any evidence that it is efficacious." - Anonymous Online Contributor